Targeted Therapy for Lung Cancer: 326 Real Stories

326 stories match lung cancer and targeted therapy. 150 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Lung CancerLung Cancer

EGFR R252C multifocal lung cancer responding to afatinib

Patient Info: Anonymized

Biomarkers: EGFR R252C extracellular-domain mutation

Afatinib was associated with suppression of primary tumor growth and extended progression-free survival in a patient with multifocal lung cancer and glioma driven by EGFR R252C. Stage and metastatic sites were not established from the available case summary.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer: persistent cough led to diagnosis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS and TP53 ; PD-L1 TPS 95%. Other common lung drivers were not detected.

Metastatic Site: liver, left adrenal gland, lymph nodes, pleural…

After more than 2 years of disease control and partial response on antiangiogenic therapy plus sintilimab, the patient developed fulminant immune-checkpoint-inhibitor-induced type 1 diabetes with severe diabetic ketoacidosis, inflammatory crisis, sepsis, and died shortly after discharge against medical advice.

PubMed Central
OutcomeIn Memory
Tina, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer treatment and follow-up story

Patient Info: Tina Powell, Female | Stage IV

As of January 2026, Tina was 3 years into Stage IV lung cancer, on a clinical trial at Memorial Sloan Kettering, and undergoing CT chest, CT pelvis, and brain MRI every 6 weeks.

YouTube (JA search)
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-Mutant Lung Adenocarcinoma With Bone and Leptomeningeal Metastases

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: bone, leptomeninges

In May 2025, leptomeningeal disease remained present and he continued combination chemotherapy with bevacizumab and high-dose furmonertinib, leaving hospital in stable condition after cycle 8.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV non-small cell lung cancer: treatment and follow-up story

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: ALK mutation/rearrangement; EGFR negative

Metastatic Site: Bone, including left humerus

As of January 2026, he described about 3 years on ALK-targeted oral therapy, feeling well, exercising 3-4 times per week, and living close to normal life with Stage IV ALK-positive lung cancer.

YouTube (ZH search)
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

MET exon 14 skipping lung adenocarcinoma: sequential MET-TKI toxicity and ongoing chemotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; EGFR negative; ALK negative; ROS1 negative; PD-L1 tumor proportion score 10%

Metastatic Site: pleura

The cancer recurred with pleural dissemination after surgery and adjuvant UFT. Sequential MET inhibitors and systemic therapies provided periods of disease control but were limited by ILD and non-ILD toxicities; at the report, he remained on carboplatin, pemetrexed, and bevacizumab.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

KRAS G12C Stage IV lung adenocarcinoma with synchronous urothelial carcinoma and durable response

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Lung adenocarcinoma: KRAS ; PD-L1 TPS 5%. Urothelial carcinoma: GATA3-positive; CK7-positive; TTF1-negative.

Metastatic Site: homolateral pulmonary metastases and N2 lymph nodes…

After enfortumab vedotin, the urothelial carcinoma reached complete radiologic response and the lung cancer remained partially responding/stable; treatment was stopped after 16 months, and PET 2 months later showed complete metabolic response.

PubMed Central
OutcomeResponding Well
Jennifer, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Jennifer's Patient Story

Patient Info: Jennifer, Female | Stage IV

Biomarkers: EGFR genomic mutation

Metastatic Site: Not reported

Jennifer is alive more than 5.5 years after a Stage IV adenocarcinoma diagnosis, continuing EGFR-targeted treatment and living with ongoing side effects and surveillance needs.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV METex14 lung adenocarcinoma: responding well to capmatinib and SBRT

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; PD-L1 >80%. EGFR/RAS/MEK wild type; lung-origin markers present.

Metastatic Site: brain; bone (thoracic/lumbar vertebrae, right iliac…

At 24 months after diagnosis, he was alive, asymptomatic, and continuing capmatinib with no evidence of progression and excellent tolerance.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR-mutated lung adenocarcinoma with suspected myocardial metastasis responding to afatinib plus chemotherapy

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR L861Q; PD-L1 TPS/CPS 65%. TP53, MET and PIK3CA alterations also reported.

Metastatic Site: left ventricular myocardium; mediastinal lymph nodes…

As of December 2025, the suspected left-ventricular myocardial metastasis had shrunk after 2 courses of afatinib plus pemetrexed/cisplatin, and the patient had no cardiovascular events during monitoring.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion: stable disease on ivonescimab plus pemetrexed

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion persisted. Later pleural fluid had PD-L1 TPS 40% / CPS 41, low TMB

Metastatic Site: pleura / malignant pleural effusion

As of August 2025, Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion was stable on ivonescimab plus pemetrexed after prior progression on gefitinib, almonertinib, and ivonescimab monotherapy.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IVB SMARCA4-deficient NSCLC with brain metastasis: stable disease after surgery, radiation, chemotherapy, immunotherapy, and bevacizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: SMARCA4/BRG-1 loss with TP53 and other mutations; TMB high; PD-L1 <1%; MSI-H not detected.

Metastatic Site: brain

As of October 2025, the patient had stable disease, no brain recurrence, a controlled left lower-lobe lung lesion, and manageable treatment toxicity while continuing bevacizumab plus pemetrexed maintenance.

PubMed Central
OutcomeLiving With Cancer
Tina, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Tina's Patient Story

Patient Info: Tina Powell, Female | Stage IV

As of November 2025, Tina was living with Stage IV lung cancer after 27 chemotherapy rounds over 3 years and was receiving an antibody-drug conjugate in a clinical trial.

YouTube (AR search)
OutcomeLiving With Cancer
Ross, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Ross's Patient Story

Patient Info: Ross Camidge, Male | Stage IV

Biomarkers: Specific mutation identified; mutation name not reported

Metastatic Site: contralateral lung; mediastinal lymph nodes; bones

After a 2022 Stage IV diagnosis, Dr. Camidge was living with metastatic lung cancer between scans and continuing treatment; he described the disease as neither cured nor actively dying.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR-mutant lung cancer: treatment and follow-up story

Patient Info: Anonymized, Female | Stage IV

Biomarkers: EGFR-mutated

As of November 2025, she was newly living with Stage IV EGFR-mutated lung cancer after starting first-generation targeted therapy on 5 March and managing treatment side effects during the first 3 months.

YouTube (ZH search)
OutcomeCare Ongoing
Laura, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Laura's Patient Story

Patient Info: Laura, Female | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

Metastatic Site: Not reported

Laura was living with incurable Stage IV ALK-positive NSCLC, continuing targeted therapy and regular CT monitoring after trying multiple TKIs and a clinical trial.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Synchronous primary squamous lung cancers: long disease control after multimodal therapy, then Stage IVA lung recurrence

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Squamous lung cancers with PD-L1 20% and no driver mutation detected; P40/P63 markers supported squamous type.

Metastatic Site: bilateral lung metastases at recurrence

As of November 2025, the patient had achieved 72 months of progression-free survival and remained alive at 75 months, but had developed Stage IVA recurrent pulmonary squamous cell carcinoma with bilateral lung metastases and had restarted systemic therapy.

PubMed Central
OutcomeSetback / Progression
Michelle, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

EGFR Non-Small Cell Lung Cancer: Michelle's Patient Story

Patient Info: Michelle Vacca, Female, 40s

Biomarkers: EGFR mutation at recurrence; later rare mutation not named

As of November 2025, Michelle still actively had recurrent NSCLC, but her disease had remained stable on targeted therapy and an investigational kinase inhibitor clinical trial, allowing good quality of life.

City of Hope
OutcomeLiving With Cancer
Drea, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ROS1 Non-Small Cell Lung Cancer: Drea's Patient Story

Patient Info: Drea, Female, Under 40 | Stage IV

Biomarkers: ROS1-positive

Metastatic Site: bilateral lungs; spine; pelvis; brain

Drea had about 3 years of good response and quality of life on her first ROS1 TKI; after new lesions appeared, a second TKI was keeping disease under control with manageable symptoms.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: 2-year survival with immunotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: SMARCA4/BRG1 loss; MET exon 14 ; BRCA1/MSH6/CDK12 mutations; PD-L1 TPS 90%; no MSI. Other common lung drivers not detected.

Metastatic Site: pleural effusion, multiple bilateral lung nodules,…

The patient declined MET inhibitor therapy and chemotherapy but responded strongly to sintilimab plus anlotinib, with marked shrinkage after 2 cycles, sustained lesion control through 32 cycles, and more than 2 years of progression-free survival.

PubMed Central
OutcomeResponding Well
Lysa, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ROS1 Non-Small Cell Lung Cancer: Lysa's Patient Story

Patient Info: Lysa, Female, 40s | Stage IV

Biomarkers: ROS1-positive / ROS1-rearranged

Metastatic Site: spine; later new sites not specified

After more than a decade with Stage IV ROS1-positive NSCLC, Lysa was stable on a clinical-trial targeted therapy and no longer needed chemotherapy.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIB RET-fusion lung adenocarcinoma: disease-free after pralsetinib, surgery and maintenance therapy

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: RET exon 12 fusion. Lung-origin markers were present

After neoadjuvant pralsetinib, surgery showed pathological complete response with negative lymph nodes. As of 16 April 2025, surveillance imaging showed no recurrence while he remained on pralsetinib 300 mg once daily.

PubMed Central
OutcomeCancer-Free / NED